Tubular glucose reabsorption is performed by the combined action of Na + /D-glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of ...

In addition: “SGLT2 inhibitors, unlike thiazolidinediones [a commonly used class of diabetes drugs], have a tendency to increase fluid excretion by a mechanism that depends on osmotic diuresis.

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

The following is a summary of "Impact of sodium-glucose cotransporter‐2 inhibitors in patients with recent versus previous ...

Unlike other inhibitors that primarily block SGLT2, this drug targets both ... “These results demonstrate a new mechanism of action—combined blockade of SGLT1 and SGLT2 receptors—to reduce ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Merck and Pfizer are hoping to cover all bases if they get their latest SGLT2 inhibitor to market. There is a crowd of already-approved rivals, but the companies are doing their best to ensure ...

as it has not been observed in trials of selective SGLT2 inhibitors." "These results demonstrate a new mechanism of action -- combined blockade with sotagliflozin of the SGLT1 receptors found in ...

Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...